Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Janus Henderson Global Life Sciences Fund Class S (JFNSX) focuses on investing in the life sciences sector, targeting companies involved in pharmaceuticals, biotechnology, and medical devices. The fund's competitive position is strengthened by its specialized investment team with deep industry expertise and a robust research framework that identifies high-growth opportunities in the global market.
The fund generates revenue primarily through management fees based on the total assets under management, which are typically charged as a percentage of AUM. The fund's competitive advantages include a strong track record in the life sciences sector, access to proprietary research, and a dedicated team of analysts with specialized knowledge in healthcare.
Performance of underlying life sciences equities in the portfolio
Changes in investor sentiment towards healthcare and biotech sectors
Regulatory developments affecting the pharmaceutical industry
Market trends in healthcare spending and innovation
Regulatory changes impacting drug approval processes and pricing
Technological disruption in healthcare delivery and pharmaceuticals
Increased competition from other specialized funds targeting life sciences
Market volatility affecting investor confidence in the sector
Liquidity risks associated with rapid AUM fluctuations
Potential pressure on fees during market downturns
moderate - The fund's performance is somewhat linked to GDP growth, as healthcare spending tends to be resilient during economic downturns but can be influenced by overall economic conditions.
Interest rates affect the fund's valuation multiples and investor appetite for equities. Rising rates may lead to increased discount rates applied to future cash flows, potentially impacting the attractiveness of growth-oriented sectors like life sciences.
minimal - The fund does not have significant credit exposure as it primarily invests in equities.
growth - Investors seeking exposure to high-growth sectors like biotech and pharmaceuticals are likely to be attracted to this fund.
moderate - The fund's historical volatility is influenced by the underlying equities in the life sciences sector, which can experience significant price fluctuations.
